EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Long-term management challenges in postmyopathic dermatomyositis

Brenna G Kelly, Richard D Sontheimer

Dermatology Online Journal · 2025

DOI: 10.25251/kjvpex37 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Dermatology Online Journal, 2025. Verfasst von Brenna G Kelly und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Utah Health Care System, Salt Lake City, UT, USA. Hauptthemen laut MEDLINE: Dermatomyositis, Piperidines, Pyrimidines, Immunoglobulins, Intravenous. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A 35-year-old woman was initially diagnosed with classic dermatomyositis (DM) at 21 years of age. We cared for her during 11 of those 14 years. Traditional immunosuppressive treatments did not control her DM skin disease activity. She was subsequently observed to have a juvenile-onset DM phenotype. For the past 11 years, her skin and muscle disease activity had been only partially controlled with monthly high-dose intravenous immunoglobulin (IVIG) therapy. During those 11 years of IVIG therapy, her skin disease activity continued to flare intermittently, and she developed cutaneous calcinosis. Both refractory skin disease activity and cutaneous calcinosis are known poor prognostic indicators for DM patients. Preliminary evidence suggests that the oral targeted synthetic Janus kinase inhibitor, tofacitinib, can provide more complete suppression of DM disease activity and possibly reverse cutaneous calcinosis. Furthermore, better suppression of DM disease activity could lower the patient’s risk of future DM comorbidities, such as premature atherosclerotic cardiovascular disease. We propose transitioning the patient from monthly high-dose IVIG to daily oral tofacitinib therapy. Another potential benefit for both the patient and society could be substantial healthcare cost savings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisPiperidinesPyrimidinesImmunoglobulins, IntravenousPyrrolesJanus Kinase InhibitorsProtein Kinase InhibitorsHumansFemaleAdultCalcinosis CutisAdministration, Oral

Stichwörter der Autor:innen

IVIGcalcinosis cutisdermatomyositispregnancytofacitinibtreat-to-target

Substanzen

PiperidinestofacitinibPyrimidinesImmunoglobulins, IntravenousPyrrolesJanus Kinase InhibitorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • University of Utah Health Care System, Salt Lake City, UT, USA.
  • Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA.

Zitieren

APA

Kelly, B. G., & Sontheimer, R. D. (2025). Long-term management challenges in postmyopathic dermatomyositis. Dermatology Online Journal. https://doi.org/10.25251/kjvpex37

Vancouver

Kelly BG, Sontheimer RD. Long-term management challenges in postmyopathic dermatomyositis. Dermatology Online Journal. 2025. doi:10.25251/kjvpex37

BibTeX
@article{Kelly2025,
  author = {Kelly, Brenna G and Sontheimer, Richard D},
  title = {Long-term management challenges in postmyopathic dermatomyositis},
  journal = {Dermatology Online Journal},
  year = {2025},
  doi = {10.25251/kjvpex37}
}
Kostenlos starten →